In a genetically engineered mouse model, SMAD4 mutations were shown to stimulate the progression of KRAS activated precursor lesions to pancreatic malignancies, indicating that SMAD4 function can inhibit the oncogenic progression of neoplasms [61]. The gene discussed is SMAD4; the disease is neoplasm.